Skip to main content
ALXO
NASDAQ Life Sciences

Director and 10% Owner Makes Substantial $5M Stock Purchase Post-Offering

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$2.19
Mkt Cap
$108.978M
52W Low
$0.404
52W High
$2.27
52W Position info
442% above low
Off High info
3.5% below high
Rel. Volume info
4.0× avg
Market data snapshot near publication time

ALXO has more than doubled off its 52-week low of $0.404 on elevated volume (4.0× avg).

Summary

A Director and 10% Owner of ALX Oncology Holdings made a nearly $5 million open market purchase of company stock, signaling strong confidence shortly after a significant public offering.


Key Events · Ownership and Investor Activity · ALXO

  • Substantial Insider Purchase

    Corey S. Goodman, a Director and 10% Owner, acquired $4,999,999 worth of common stock in an open market transaction on February 2, 2026.

  • Post-Offering Confidence Signal

    This significant purchase occurred just days after the company finalized a $150 million public offering on January 30, 2026, indicating strong insider conviction despite recent dilution.

  • Significant Stake Increase

    The transaction represents a substantial investment relative to the company's market capitalization, increasing the reporting owner's indirect holdings to 8,453,038 shares.


Analysis · ALXO · Life Sciences

Corey S. Goodman, a Director and 10% Owner, made a significant open market purchase of nearly $5 million in ALX Oncology Holdings stock. This substantial investment, representing a notable portion of the company's market capitalization, occurred just days after the company finalized a $150 million public offering on January 30, 2026. The timing of this large insider buy, especially following a dilutive capital raise, signals strong confidence in the company's future prospects and the value of its shares. The stock is also trading near its 52-week high, further underscoring the conviction behind this purchase.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ALXO was trading at $2.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $109M. The 52-week trading range was $0.40 to $2.27. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ALXO - Latest Insights

ALXO
Oct 15, 2026, 4:55 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9709
Real-time Price: $1.00 info
Change: +$0.0291 (+3%) info
Market Cap: $143.808M info
ALXO
Sep 28, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.30
Real-time Price: $1.00 info
Change: -$0.300 (-23%) info
Market Cap: $143.808M info
ALXO
Aug 06, 2026, 8:16 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.92
Real-time Price: $1.00 info
Change: -$0.920 (-48%) info
Market Cap: $143.808M info
ALXO
Aug 06, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.92
Real-time Price: $1.00 info
Change: -$0.920 (-48%) info
Market Cap: $143.808M info
ALXO
Jun 30, 2026, 4:03 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.07
Real-time Price: $1.00 info
Change: -$1.07 (-52%) info
Market Cap: $143.808M info